Beijing’s First Biopharma Projects Get Over RMB 10 Billion In Loans
This article was originally published in PharmAsia News
Beijing’s Financial Incentive Pilot Scheme has loaned around 260 biopharma companies more than RMB 10 billion, including RMB 1 billion for 65 small and medium enterprises in the past two years
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.